Ruxolitinib (INCB018424) is an Orally Active JAK1 and JAK2 Inhibitor
The myeloproliferative neoplasms (MPNs) are a group of related clonal diseases probably arising from hematopoietic progenitor or stem cells. Patients with MPNs have an increased risk of thrombotic and bleeding…